Paper

Hybrid graphene oxide as carrier of doxorubicin: cytotoxicity and preliminary in vivo assays against bladder cancer

, , , , , , and

Published 25 May 2020 © 2020 Vietnam Academy of Science & Technology
, , Citation Wagner J Fávaro et al 2020 Adv. Nat. Sci: Nanosci. Nanotechnol. 11 025016 DOI 10.1088/2043-6254/ab9194

2043-6262/11/2/025016

Abstract

Two types of graphene oxide (GO) hybrids were synthesised for the administration of doxorubicin (DOX, named GO-CO-DOX) and interfering RNA - siRNA (named GO-PEG-PEI/siRNA). These nanomaterials were used for intervention on vascular endothelial growth factor (VEGF) that represents an important strategy to block the formation of new vessels to inhibit cancer progression. For the delivery of DOX, it was incorporated into GO, while for the delivery of siRNA, GO was covalently bonded with the cationic polyethyleneimine (PEI) and then complexed with siRNA. The nanostructures were characterised by attenuated total reflection ATR-FTIR, zeta potential, x-ray photoelectron spectroscopy (XPS), x-ray diffraction (XRD), and transmission electron microscopy (TEM). The cytotoxicity studies with GO-PEG-PEI and GO-PEG-PEI/siRNA systems showed that both formulations have IC50 values of around 100 μg ml−1. The systems were administered in vivo to investigate their antitumor effects against non-muscle-invasive bladder cancer (NMIBC) and showed to be promising for the treatment of NMIBC.

Export citation and abstract BibTeX RIS

Access this article

The computer you are using is not registered by an institution with a subscription to this article. Please choose one of the options below.

Login

IOPscience login

Find out more about journal subscriptions at your site.

Purchase from

Article Galaxy
CCC RightFind

Purchase this article from our trusted document delivery partners.

Make a recommendation

To gain access to this content, please complete the Recommendation Form and we will follow up with your librarian or Institution on your behalf.

For corporate researchers we can also follow up directly with your R&D manager, or the information management contact at your company. Institutional subscribers have access to the current volume, plus a 10-year back file (where available).

10.1088/2043-6254/ab9194